Newsletters

[Pilatus Biosciences Inc.] Pilatus Biosciences Inc. announced that the US FDA has granted Fast Track designation for PLT012, the company’s first-in-class anti-CD36 monoclonal antibody for the treatment of hepatocellular carcinoma.

[Nature] Scientists found that systemic or hepatocyte-specific ablation of the gene encoding glycoprotein non-metastatic melanoma protein B (Gpnmb)—a top upregulated gene in metabolic-dysfunction-associated steatohepatitis (MASH)—protected mice from diet-induced MASH.

[Molecular Cancer] Researchers demonstrated the key role of enhancer of zest homologue 2 (EZH2) in proliferative hepatoblastoma and the therapeutic benefit of combining EZH2 inhibitor and statin to treat patients with cancer.

[Environmental Science & Technology] Using long-term in vitro and in vivo exposure models with environmentally relevant doses combined with multiomics analyses, investigators showed that per- and polyfluoroalkyl substances exert antithetical effects in hepatocellular carcinoma and normal hepatocytes.

[Cell Death & Disease] Scientists indicated that peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) inhibited hepatocyte ferroptosis and attenuated metabolic dysfunction-associated steatohepatitis (MASH) by upregulating Tim23 and inhibiting the Drp1-ACSL4 axis.

[Journal of Nanobiotechnology] The authors demonstrated that M2 macrophage-derived apoptotic extracellular vesicle alleviate liver fibrosis by modulating hepatic stellate cells activation.

[Discover Oncology] Researchers performed a comprehensive multi-omics analysis integrating bulk and single-cell transcriptomic data to investigate the expression pattern, clinical relevance, immune landscape, and functional roles of FKBP10 in hepatocellular carcinoma.

[Current Obesity Reports] Scientists summarize the available data on the link between adult growth hormone deficiency and metabolic dysfunction-associated steatotic liver disease, focusing on possible pathophysiological mechanisms, clinical associations, and treatment considerations.

[Signal Transduction and Targeted Therapy] Researchers investigated the mechanistic role of parathyroid hormone–related protein_1-34 in pulmonary fibrosis both in vitro and using in vivo models and proposed different strategies for blocking idiopathic pulmonary fibrosis progression.

[Nature Communications] Using well-established acute lung injury and sepsis models, scientists demonstrated that brain-derived neurotrophic factor, a key neurotrophic factor, is impaired in pulmonary epithelial cells and negatively correlates with the inflammatory response.

[Nature Communications] Investigators performed a drug screening with an in vitro pulmonary fibrosis model using fibroblast-dependent alveolar organoids derived from hiPSCs and identified p300/CBP inhibitors as candidate therapeutic agents.

[RMD Open] To assess anlotinib’s therapeutic effects, researchers established a MAILD mouse model and a neutrophil extracellular trap (NET)-induced human alveolar epithelial cell model.